Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers
Year: 2019
Type: article
Study design: Observational Study
Abstract: BACKGROUND: ) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomarkers reflecting central nervous system pathophysiology and should be fully explored for biomarkers that show promise in CSF. Recently, soluble fragments of the triggering receptor expressed on myeloid cells 2 (sTREM2) protein in CSF have been reported to be increased in prodromal AD and also in individuals with TREM2 rare genetic variants that increase the likelihood of developing dementia. METHODS: In this study, we measured the levels of plasma sTREM2 and plasma NFL using the MesoScale Discovery and single molecule array platforms, respectively, in 48 confirmed TREM2 rare variant carriers and 49 non-carriers. RESULTS: Our results indicate that there are no changes in plasma sTREM2 and NFL concentrations between TREM2 rare variant carriers and non-carriers. Furthermore, plasma sTREM2 is not different between healthy controls, mild cognitive impairment (MCI) or AD. CONCLUSION: Concentrations of plasma sTREM2 do not mimic the recent changes found in CSF sTREM2.
Source: Alzheimer s Research & Therapy
Institutions: King's College London, South London and Maudsley NHS Foundation Trust, Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Pasqual Maragall Foundation, Barcelonaβeta Brain Research Center, Hospital Del Mar, UK Dementia Research Institute, UCL Queen Square Institute of Neurology, University College London, Instituto de Salud Carlos III, Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition, Navarre Institute of Health Research, Centro de Investigación Biomédica en Red, Universidad de Navarra, University Hospital Mútua de Terrassa, Mútua Terrassa, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Maastricht University, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Sahlgrenska University Hospital
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,580
Funders: Torsten Söderbergs Stiftelse, South London and Maudsley NHS Foundation Trust, Wellcome Trust, European Federation of Pharmaceutical Industries and Associations, National Institute for Health and Care Research, King's College London, European Commission, Vetenskapsrådet, UK Dementia Research Institute, Instituto de Salud Carlos III, H2020 European Research Council
Awards: G1158107345, G434337789, The effect of pro-aging and pro-youthful blood factors in normal ageing and Alzheimer’s disease: a multimodal approach, G6069138294, Pathways to Alzheimer's disease, G7198253607, Inflammation and AD: modulating microglia function focussing on TREM2 and CD33 - Sofia ref.: 115976, What determines amyloid beta aggregation and toxicity in Alzheimer’s disease?
OpenAlex ID: W2990955852
